ArticleGastro hep advances2026
Efficacy of Upadacitinib Retreatment or Dose Escalation After Loss of Response in Ulcerative Colitis: Data From the Open-Label Extension of the U-ACTIVATE Study.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects With Ulcerative Colitis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Upadacitinib (UPA) is a Janus kinase inhibitor approved for moderately to severely active ulcerative colitis (UC). Patients may discontinue and then restart UPA treatment or require dose adjustment; however, the impact on overall efficacy of treatment interruption or dose escalation is not fully characterized. This analysis of the U-ACTIVATE (NCT03006068) open-label extension (OLE) study evaluated the efficacy of UPA retreatment after UPA withdrawal or dose escalation during UPA maintenance following a loss of response in patients with UC. Methods: Patients who responded to 8 weeks of UPA 45 mg induction therapy were rerandomized to placebo, UPA 15 mg (UPA15), or 30 mg (UPA30) in the 52-week U-ACHIEVE (NCT02819635) maintenance study. Patients who subsequently lost response on placebo during maintenance could enter the U-ACTIVATE OLE and were retreated with UPA at a 15 mg dose (UPA retreatment group); patients who lost response on maintenance UPA15 continued UPA15 during the OLE. Patients who lost response on UPA15 during the OLE and met prespecified criteria were escalated to UPA30. Clinical and endoscopic remissions were assessed through week 144. Safety was not assessed in this analysis but has been reported previously. Results: The UPA retreatment group enrolled 110 patients; 57 remained on UPA15 (UPA15OLE→UPA15) and 47 were escalated to UPA30 (UPA15OLE→UPA30) by week 144. A total of 39 patients lost response on maintenance UPA15 and entered the OLE on UPA30 (UPA15Maint→UPA30). At week 144, the following proportion of patients achieved clinical remission per adapted Mayo score and endoscopic remission, respectively: UPA15OLE→UPA15: 76.3% and 33.3%, UPA15OLE→UPA30: 61.1% and 56.4%, and UPA15Maint→UPA30: 43.5% and 40.7%. Conclusion: In patients with UC, clinical and endoscopic efficacy could be recaptured following UPA retreatment or dose escalation in the U-ACTIVATE OLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.